Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
More News related to DNA
- Piper Jaffray Reiterates an 'Overweight' on Regeneron Pharmaceuticals (REGN); Raises Price Target
- Biogen Idec (BIIB) Announces Decision By Arbitration Panel in Issues with Genentech (DNA)
- Genentech (DNA) Announces Voluntary Withdrawal of Raptiva from the U.S. Market
- FDA ODA Committee Recommends Accelerated Approval of Genentech's (DNA) Avastin for Brain Cancer
- Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
Genentech (NYSE: DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer.
Related Categories
FDAHot List
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
